CC-90009
- Generic Name
- CC-90009
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Phase 1
Terminated
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Celgene
- Target Recruit Count
- 22
- Registration Number
- NCT04336982
- Locations
- 🇺🇸
Local Institution - 104, San Francisco, California, United States
🇺🇸Local Institution - 103, Boston, Massachusetts, United States
🇨🇦Local Institution - 201, Toronto, Ontario, Canada
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 8
- Registration Number
- NCT04297124
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Phase 1
Terminated
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 101
- Registration Number
- NCT02848001
- Locations
- 🇺🇸
Local Institution - 104, Hackensack, New Jersey, United States
🇨🇦Local Institution - 201, Toronto, Ontario, Canada
🇳🇴Local Institution - 701, Oslo, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath